Wellington Partners tanks up with $237M for its next life sci fund — same strategy, but with more cash on hand
A year ago, when Philadelphia-based Carisma Therapeutics was raising a $53 million A round to back their work on macrophages in immuno-oncology, Munich-based Wellington Partners stepped in with the new crowd to take a ringside seat.
That was a bit unusual for the life sciences crew at Wellington, which tends to stay closer to home with investments in the German-speaking region of European biotech — concentrating on startups like Immatics. But then after 22 years in the investing game, there’s also a sense that they don’t want to be completely tied down by too many self-imposed rules.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
